A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 versus EU sourced MabThera in Anti TNF Inadequate Responder Patients with Moderate to Severe RA on Background MTX Therapy
Phase of Trial: Phase I
Latest Information Update: 25 May 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors JHL Biotech
- 29 Mar 2017 Status changed from not yet recruiting to recruiting, according to a JHL Biotech media release.
- 29 Mar 2017 According to a JHL Biotech media release, the first patient in this trial has been dosed.
- 08 Jul 2016 Last checked against United Kingdom Clinical Research Network record.